MPLT — MapLight Therapeutics Share News
0.000.00%
Last trade - 00:00- $436.00m
- $131.27m
U.S. RESEARCH ROUNDUP- BioLife Solutions, Gossamer Bio, Intuit
MapLight's schizophrenia drug fails once-daily test, shares plunge
U.S. RESEARCH ROUNDUP-Deckers Brands, Rollins, United Rentals
U.S. STOCKS ON THE MOVE-Abbvie, AMC, Getty
U.S. STOCKS ON THE MOVE-Getty Images, Ecarx, Maplight Therapeutics
Maplight Therapeutics rises as autism drug shows benefit in subset despite trial miss
Brief: Maplight Announces Topline Results From Phase 2 Iris Study For Ml-004 In Autism Spectrum Disorder
Brief: Maplight Therapeutics Says Vishwas Setia Separated As CFO Effective June 18
U.S. STOCKS ON THE MOVE-Meta, Legence, Chegg
U.S. STOCKS ON THE MOVE-Hims & Hers, Chewy, Longeveron
U.S. STOCKS ON THE MOVE-Delta, Levi's, banks
U.S. STOCKS ON THE MOVE-Delta, GATX, Humana
Needham initiates coverage of MapLight on schizophrenia drug potential
Aktis Oncology files for US IPO as biotech listings rebound
Brief: Sandboxaq And Maplight Therapeutics Announce Collaboration To Discover And Develop Novel CNS Therapies
Brief: Maplight Therapeutics Reports Third Quarter Financial Results
U.S. RESEARCH ROUNDUP-Bath & Body Works, Elastic, Walmart
U.S. RESEARCH ROUNDUP- Bath & Body Works, Elastic, Walmart
MapLight Therapeutics valued at $787 million as shares jump in Nasdaq debut (updated)